Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Boston Scientific management to meet virtually with BTIG » 04:55
05/19/22
05/19
04:55
05/19/22
04:55
BSX

Boston Scientific

$40.22 /

-1.09 (-2.64%)

Medical Technology and…

Medical Technology and Digital Health Analyst Thibault holds a virtual meeting with management on May 19 hosted by BTIG.

ShowHide Related Items >><<
BSX Boston Scientific
$40.22 /

-1.09 (-2.64%)

BSX Boston Scientific
$40.22 /

-1.09 (-2.64%)

05/17/22 Citi
Boston Scientific price target lowered to $47 from $52 at Citi
05/16/22 Morgan Stanley
Boston Scientific named a 'Top Pick' at Morgan Stanley after meeting with CEO
05/03/22 Piper Sandler
Piper raises Zimmer Biomet target to $130, but sees 'better large caps to own'
04/27/22 Piper Sandler
Boston Scientific beat and modest raise 'a welcome sight,' says Piper Sandler
BSX Boston Scientific
$40.22 /

-1.09 (-2.64%)

BSX Boston Scientific
$40.22 /

-1.09 (-2.64%)

BSX Boston Scientific
$40.22 /

-1.09 (-2.64%)

BSX Boston Scientific
$40.22 /

-1.09 (-2.64%)

Over a week ago
Recommendations
Boston Scientific price target lowered to $47 from $52 at Citi » 06:24
05/17/22
05/17
06:24
05/17/22
06:24
BSX

Boston Scientific

$39.83 /

+0.175 (+0.44%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch lowered the firm's price target on Boston Scientific to $47 from $52 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch.

ShowHide Related Items >><<
BSX Boston Scientific
$39.83 /

+0.175 (+0.44%)

BSX Boston Scientific
$39.83 /

+0.175 (+0.44%)

05/16/22 Morgan Stanley
Boston Scientific named a 'Top Pick' at Morgan Stanley after meeting with CEO
05/03/22 Piper Sandler
Piper raises Zimmer Biomet target to $130, but sees 'better large caps to own'
04/27/22 Piper Sandler
Boston Scientific beat and modest raise 'a welcome sight,' says Piper Sandler
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
BSX Boston Scientific
$39.83 /

+0.175 (+0.44%)

BSX Boston Scientific
$39.83 /

+0.175 (+0.44%)

BSX Boston Scientific
$39.83 /

+0.175 (+0.44%)

BSX Boston Scientific
$39.83 /

+0.175 (+0.44%)

Recommendations
Boston Scientific named a 'Top Pick' at Morgan Stanley after meeting with CEO » 06:44
05/16/22
05/16
06:44
05/16/22
06:44
BSX

Boston Scientific

$39.65 /

+0.87 (+2.24%)

Morgan Stanley analyst…

Morgan Stanley analyst Cecilia Furlong noted that she recently spent an hour with Boston Scientific's CEO Mike Mahoney, after which she named the stock her "Top Pick" as the conversation left her with increased confidence in Boston's ability to hit near-term targets with growth drivers beyond. Boston Scientific's recent analyst day reaffirmed above-peer growth targets and double-digit EPS growth for the foreseeable future, noted Furlong, who has an Overweight rating and $51 price target on the shares.

ShowHide Related Items >><<
BSX Boston Scientific
$39.65 /

+0.87 (+2.24%)

BSX Boston Scientific
$39.65 /

+0.87 (+2.24%)

05/03/22 Piper Sandler
Piper raises Zimmer Biomet target to $130, but sees 'better large caps to own'
04/27/22 Piper Sandler
Boston Scientific beat and modest raise 'a welcome sight,' says Piper Sandler
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
BSX Boston Scientific
$39.65 /

+0.87 (+2.24%)

BSX Boston Scientific
$39.65 /

+0.87 (+2.24%)

BSX Boston Scientific
$39.65 /

+0.87 (+2.24%)

BSX Boston Scientific
$39.65 /

+0.87 (+2.24%)

Earnings
Prometheus reports Q1 EPS (82c), consensus (79c) » 16:07
05/12/22
05/12
16:07
05/12/22
16:07
RXDX

Prometheus

$23.36 /

+1.05 (+4.71%)

"I couldn't be…

"I couldn't be more pleased with the execution our team has demonstrated during a very challenging external backdrop. Despite significant global headwinds and our aggressive timelines, we are still on track to deliver on our near-term milestones, namely the topline results from our Artemis-UC Phase 2 and Apollo-CD Phase 2a trials in the fourth quarter this year," said Mark McKenna, Chairman and CEO. Upcoming milestone vents: Update on UC and CD Phase 2 enrollment planned in 2Q; IND submission for PR600 planned for 3Q; Topline results from the ARTEMIS-UC Phase 2 study expected in 4Q; Topline results from APOLLO-CD Phase 2a study expected in 4Q.

ShowHide Related Items >><<
RXDX Prometheus
$23.36 /

+1.05 (+4.71%)

RXDX Prometheus
$23.36 /

+1.05 (+4.71%)

03/10/22 Wells Fargo
Prometheus price target raised to $53 from $42 at Wells Fargo
02/11/22 BTIG
Prometheus initiated with a Buy at BTIG
02/11/22 BTIG
Prometheus initiated with a Buy at BTIG
12/13/21 RBC Capital
Prometheus initiated with an Outperform at RBC Capital
RXDX Prometheus
$23.36 /

+1.05 (+4.71%)

Conference/Events
Boston Scientific management to meet virtually with BTIG » 12:57
05/12/22
05/12
12:57
05/12/22
12:57
BSX

Boston Scientific

$38.61 /

-0.14 (-0.36%)

Medical Technology and…

Medical Technology and Digital Health Analyst Thibault holds a virtual meeting with management on May 19 hosted by BTIG.

ShowHide Related Items >><<
BSX Boston Scientific
$38.61 /

-0.14 (-0.36%)

BSX Boston Scientific
$38.61 /

-0.14 (-0.36%)

05/03/22 Piper Sandler
Piper raises Zimmer Biomet target to $130, but sees 'better large caps to own'
04/27/22 Piper Sandler
Boston Scientific beat and modest raise 'a welcome sight,' says Piper Sandler
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
BSX Boston Scientific
$38.61 /

-0.14 (-0.36%)

BSX Boston Scientific
$38.61 /

-0.14 (-0.36%)

BSX Boston Scientific
$38.61 /

-0.14 (-0.36%)

BSX Boston Scientific
$38.61 /

-0.14 (-0.36%)

Recommendations
Piper raises Zimmer Biomet target to $130, but sees 'better large caps to own' » 13:44
05/03/22
05/03
13:44
05/03/22
13:44
ZBH

Zimmer Biomet

$122.68 /

+1.98 (+1.64%)

, BSX

Boston Scientific

$41.93 /

+0.31 (+0.74%)

, DXCM

DexCom

$398.54 /

-8.42 (-2.07%)

, SYK

Stryker

$238.31 /

+1.49 (+0.63%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on Zimmer Biomet (ZBH) to $130 from $110 and keeps a Neutral rating on the shares after the company reported Q1 results that beat "modest expectations" and raised guidance from what he calls "a very soft initial view on the year." While he believes the backlog of orthopedic cases starting to filter through the system is a positive and notes that the inflationary effect on Zimmer Biomet is not as negative as he feared, O'Brien continues to see more attractive growth names across the large cap med tech universe that he continues to favor, such as Boston Scientific (BSX), DexCom (DXCM) and Stryker (SYK).

ShowHide Related Items >><<
ZBH Zimmer Biomet
$122.68 /

+1.98 (+1.64%)

SYK Stryker
$238.31 /

+1.49 (+0.63%)

DXCM DexCom
$398.54 /

-8.42 (-2.07%)

BSX Boston Scientific
$41.93 /

+0.31 (+0.74%)

ZBH Zimmer Biomet
$122.68 /

+1.98 (+1.64%)

04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Zimmer Biomet assumed at Hold from Buy at Truist
04/06/22 JPMorgan
JPMorgan 'tentatively bullish' on medtech, sees two best positioned
BSX Boston Scientific
$41.93 /

+0.31 (+0.74%)

04/27/22 Piper Sandler
Boston Scientific beat and modest raise 'a welcome sight,' says Piper Sandler
04/12/22 Truist
Boston Scientific assumed with a Buy at Truist
DXCM DexCom
$398.54 /

-8.42 (-2.07%)

04/29/22 SVB Leerink
DexCom price target lowered to $500 from $565 at SVB Leerink
04/29/22 Canaccord
DexCom price target lowered to $500 from $525 at Canaccord
04/29/22 Raymond James
DexCom price target lowered to $486 from $538 at Raymond James
04/29/22 Piper Sandler
DexCom price target lowered to $480 from $725 at Piper Sandler
SYK Stryker
$238.31 /

+1.49 (+0.63%)

05/02/22 Truist
Stryker price target lowered to $280 from $296 at Truist
04/29/22 Piper Sandler
Stryker price target lowered to $290 from $315 at Piper Sandler
04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
ZBH Zimmer Biomet
$122.68 /

+1.98 (+1.64%)

SYK Stryker
$238.31 /

+1.49 (+0.63%)

DXCM DexCom
$398.54 /

-8.42 (-2.07%)

BSX Boston Scientific
$41.93 /

+0.31 (+0.74%)

SYK Stryker
$238.31 /

+1.49 (+0.63%)

BSX Boston Scientific
$41.93 /

+0.31 (+0.74%)

ZBH Zimmer Biomet
$122.68 /

+1.98 (+1.64%)

SYK Stryker
$238.31 /

+1.49 (+0.63%)

DXCM DexCom
$398.54 /

-8.42 (-2.07%)

BSX Boston Scientific
$41.93 /

+0.31 (+0.74%)

ZBH Zimmer Biomet
$122.68 /

+1.98 (+1.64%)

SYK Stryker
$238.31 /

+1.49 (+0.63%)

DXCM DexCom
$398.54 /

-8.42 (-2.07%)

BSX Boston Scientific
$41.93 /

+0.31 (+0.74%)

Recommendations
Boston Scientific beat and modest raise 'a welcome sight,' says Piper Sandler » 14:56
04/27/22
04/27
14:56
04/27/22
14:56
BSX

Boston Scientific

$43.61 /

+0.97 (+2.27%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien notes Boston Scientific reported Q1 results with both sales and EPS coming in ahead of expectations. Management raised guidance slightly on the top- and bottom-lines, the latter of which was a welcome update given all the inflationary pressures the company and Med Tech is experiencing, the analyst contends. O'Brien adds that gross margins will be under pressure for the year but some of these headwinds should abate late in the year and into 2023, setting the company up to be a strong grower and margin expansion story as well. With many of the key growth drivers intact there is a lot to like about the name, the analyst says. O'Brien reiterates an Overweight rating on the shares with a price target of $50.

ShowHide Related Items >><<
BSX Boston Scientific
$43.61 /

+0.97 (+2.27%)

BSX Boston Scientific
$43.61 /

+0.97 (+2.27%)

04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Boston Scientific assumed with a Buy at Truist
04/06/22 JPMorgan
JPMorgan 'tentatively bullish' on medtech, sees two best positioned
BSX Boston Scientific
$43.61 /

+0.97 (+2.27%)

BSX Boston Scientific
$43.61 /

+0.97 (+2.27%)

BSX Boston Scientific
$43.61 /

+0.97 (+2.27%)

BSX Boston Scientific
$43.61 /

+0.97 (+2.27%)

On The Fly
Fly Intel: Pre-market Movers » 09:15
04/27/22
04/27
09:15
04/27/22
09:15
MAT

Mattel

$22.14 /

-1.055 (-4.55%)

, TMUS

T-Mobile

$124.90 /

-3.96 (-3.07%)

, GD

General Dynamics

$237.06 /

-2 (-0.84%)

, BSX

Boston Scientific

$42.63 /

-1.955 (-4.38%)

, NEO

NeoGenomics

$10.83 /

-0.45 (-3.99%)

, V

Visa

$201.21 /

-9.03 (-4.30%)

, MSFT

Microsoft

$270.08 /

-10.79 (-3.84%)

, BA

Boeing

$166.91 /

-8.84 (-5.03%)

, HOG

Harley-Davidson

$36.50 /

-1.77 (-4.63%)

, NCR

NCR Corp.

$37.26 /

-2.74 (-6.85%)

, GOOGL

Alphabet Class A

$2,377.31 /

-84.82 (-3.44%)

, HOOD

Robinhood

$10.00 /

-0.405 (-3.89%)

Check out this morning's…

ShowHide Related Items >><<
V Visa
$201.21 /

-9.03 (-4.30%)

TMUS T-Mobile
$124.90 /

-3.96 (-3.07%)

NEO NeoGenomics
$10.83 /

-0.45 (-3.99%)

NCR NCR Corp.
$37.26 /

-2.74 (-6.85%)

MSFT Microsoft
$270.08 /

-10.79 (-3.84%)

MAT Mattel
$22.14 /

-1.055 (-4.55%)

HOOD Robinhood
$10.00 /

-0.405 (-3.89%)

HOG Harley-Davidson
$36.50 /

-1.77 (-4.63%)

GOOGL Alphabet Class A
$2,377.31 /

-84.82 (-3.44%)

GD General Dynamics
$237.06 /

-2 (-0.84%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BA Boeing
$166.91 /

-8.84 (-5.03%)

MAT Mattel
$22.14 /

-1.055 (-4.55%)

02/24/22 JPMorgan
Mattel shares 'remain cheap' at current levels, says JPMorgan
02/24/22 Stifel
Mattel upgraded to Buy from Hold at Stifel
02/14/22 DA Davidson
Mattel price target raised to $45 from $38 at DA Davidson
02/10/22 Monness Crespi
Mattel price target raised to $32 from $28 at Monness Crespi
TMUS T-Mobile
$124.90 /

-3.96 (-3.07%)

03/23/22 KeyBanc
KeyBanc upgrades T-Mobile to Overweight with $155 price target
03/23/22 KeyBanc
T-Mobile upgraded to Overweight from Sector Weight at KeyBanc
03/14/22 Citi
T-Mobile price target raised to $156 from $155 at Citi
03/11/22 Tigress Financial
T-Mobile initiated with a Buy at Tigress Financial
GD General Dynamics
$237.06 /

-2 (-0.84%)

03/29/22 Jefferies
Northrop among biggest beneficiaries of DoD budget request, says Jefferies
03/07/22 Wells Fargo
General Dynamics price target raised to $282 from $235 at Wells Fargo
02/04/22 Morgan Stanley
Morgan Stanley upgrades General Dynamics to Equal Weight on Gulfstream outlook
02/04/22 Morgan Stanley
General Dynamics upgraded to Equal Weight from Underweight at Morgan Stanley
BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Boston Scientific assumed with a Buy at Truist
04/06/22 JPMorgan
JPMorgan 'tentatively bullish' on medtech, sees two best positioned
NEO NeoGenomics
$10.83 /

-0.45 (-3.99%)

03/29/22 Cowen
NeoGenomics price target lowered to $24 from $42 at Cowen
03/29/22 BTIG
NeoGenomics price target lowered to $28 from $35 at BTIG
03/29/22 SVB Leerink
NeoGenomics price target lowered to $20 from $45 at SVB Leerink
03/29/22 Needham
NeoGenomics price target lowered to $19 from $29 at Needham
V Visa
$201.21 /

-9.03 (-4.30%)

04/27/22 Cowen
Visa price target lowered to $254 from $276 at Cowen
04/27/22 Morgan Stanley
Visa price target raised to $284 from $279 at Morgan Stanley
04/27/22 Credit Suisse
Visa price target raised to $265 from $260 at Credit Suisse
04/25/22 Citi
Visa price target lowered to $265 from $285 at Citi
MSFT Microsoft
$270.08 /

-10.79 (-3.84%)

04/27/22 Morgan Stanley
Morgan Stanley buyers of Microsoft after Q3 results, 'robust' guidance
04/27/22 Oppenheimer
Microsoft Azure accelerates constant-currency growth to 49%, says Oppenheimer
04/27/22 Wedbush
Microsoft price target lowered to $340 from $375 at Wedbush
04/27/22 Stifel
Microsoft price target lowered to $350 from $380 at Stifel
BA Boeing
$166.91 /

-8.84 (-5.03%)

04/22/22 Benchmark
Boeing price target lowered to $250 from $270 at Benchmark
04/21/22 JPMorgan
Boeing progress with 787 good news, says JPMorgan
04/08/22 Morgan Stanley
Boeing price target lowered to $230 from $288 at Morgan Stanley
03/30/22 Jefferies
China Southern's 3-year outlook from Boeing down 20 aircraft, says Jefferies
HOG Harley-Davidson
$36.50 /

-1.77 (-4.63%)

02/09/22 Baird
Harley-Davidson price target raised to $60 from $50 at Baird
02/09/22 Morgan Stanley
Harley-Davidson price target raised to $44 from $40 at Morgan Stanley
02/01/22 Morgan Stanley
Harley-Davidson upgraded to Equal Weight from Underweight at Morgan Stanley
10/28/21 BMO Capital
Harley-Davidson price target raised to $62 from $54 at BMO Capital
NCR NCR Corp.
$37.26 /

-2.74 (-6.85%)

04/27/22 Morgan Stanley
NCR Corp. price target lowered to $40 from $61 at Morgan Stanley
01/03/22 Stephens
Wendy's, Kirby and Vizio among Stephens' 2022 Best Ideas
11/18/21 Stephens
NCR Corp. initiated with an Overweight at Stephens
10/27/21 RBC Capital
NCR Corp. price target lowered to $54 from $59 at RBC Capital
GOOGL Alphabet Class A
$2,377.31 /

-84.82 (-3.44%)

04/27/22 Guggenheim
Alphabet price target lowered to $3,000 from $3,350 at Guggenheim
04/27/22 Jefferies
Alphabet price target lowered to $3,400 from $3,600 at JefferiesAlphabet
04/27/22 Truist
Alphabet price target lowered to $3,500 from $3,600 at Truist
04/27/22 Wells Fargo
Alphabet price target lowered to $3,400 from $3,600 at Wells Fargo
HOOD Robinhood
$10.00 /

-0.405 (-3.89%)

04/19/22 JMP Securities
Ziglu deal should accelerate Robinhood's crypto expansion, says JMP Securities
04/08/22 Goldman Sachs
Robinhood downgraded to Sell from Neutral at Goldman Sachs
04/07/22 Cowen
Yellen remarks 'tacit support' for Gensler's crypto regulations, Cowen says
04/07/22 Deutsche Bank
Robinhood price target lowered to $11 from $14 at Deutsche Bank
V Visa
$201.21 /

-9.03 (-4.30%)

TMUS T-Mobile
$124.90 /

-3.96 (-3.07%)

NEO NeoGenomics
$10.83 /

-0.45 (-3.99%)

NCR NCR Corp.
$37.26 /

-2.74 (-6.85%)

MSFT Microsoft
$270.08 /

-10.79 (-3.84%)

MAT Mattel
$22.14 /

-1.055 (-4.55%)

HOOD Robinhood
$10.00 /

-0.405 (-3.89%)

HOG Harley-Davidson
$36.50 /

-1.77 (-4.63%)

GOOGL Alphabet Class A
$2,377.31 /

-84.82 (-3.44%)

GD General Dynamics
$237.06 /

-2 (-0.84%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BA Boeing
$166.91 /

-8.84 (-5.03%)

  • 09
    Sep
  • 29
    Jul
V Visa
$201.21 /

-9.03 (-4.30%)

TMUS T-Mobile
$124.90 /

-3.96 (-3.07%)

MSFT Microsoft
$270.08 /

-10.79 (-3.84%)

MAT Mattel
$22.14 /

-1.055 (-4.55%)

HOOD Robinhood
$10.00 /

-0.405 (-3.89%)

HOG Harley-Davidson
$36.50 /

-1.77 (-4.63%)

GOOGL Alphabet Class A
$2,377.31 /

-84.82 (-3.44%)

GD General Dynamics
$237.06 /

-2 (-0.84%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BA Boeing
$166.91 /

-8.84 (-5.03%)

V Visa
$201.21 /

-9.03 (-4.30%)

TMUS T-Mobile
$124.90 /

-3.96 (-3.07%)

NEO NeoGenomics
$10.83 /

-0.45 (-3.99%)

NCR NCR Corp.
$37.26 /

-2.74 (-6.85%)

MSFT Microsoft
$270.08 /

-10.79 (-3.84%)

MAT Mattel
$22.14 /

-1.055 (-4.55%)

HOOD Robinhood
$10.00 /

-0.405 (-3.89%)

HOG Harley-Davidson
$36.50 /

-1.77 (-4.63%)

GOOGL Alphabet Class A
$2,377.31 /

-84.82 (-3.44%)

GD General Dynamics
$237.06 /

-2 (-0.84%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BA Boeing
$166.91 /

-8.84 (-5.03%)

V Visa
$201.21 /

-9.03 (-4.30%)

TMUS T-Mobile
$124.90 /

-3.96 (-3.07%)

NCR NCR Corp.
$37.26 /

-2.74 (-6.85%)

MSFT Microsoft
$270.08 /

-10.79 (-3.84%)

MAT Mattel
$22.14 /

-1.055 (-4.55%)

HOOD Robinhood
$10.00 /

-0.405 (-3.89%)

HOG Harley-Davidson
$36.50 /

-1.77 (-4.63%)

GOOGL Alphabet Class A
$2,377.31 /

-84.82 (-3.44%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BA Boeing
$166.91 /

-8.84 (-5.03%)

Earnings
Boston Scientific sees FY22 adjusted EPS $1.74-$1.79, consensus $1.77 » 06:36
04/27/22
04/27
06:36
04/27/22
06:36
BSX

Boston Scientific

$42.63 /

-1.955 (-4.38%)

Sees FY22 revenue up…

Sees FY22 revenue up 7%-9%, consensus $12.84B. The company said, "The company now estimates net sales growth for the full year 2022, versus the prior year period, to be in a range of approximately 7 to 9 percent on a reported basis, and approximately 6.5 to 8.5 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates EPS on a GAAP basis in a range of $0.78 to $0.88 and estimates adjusted EPS, excluding certain charges (credits), of $1.74 to $1.79."

ShowHide Related Items >><<
BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Boston Scientific assumed with a Buy at Truist
04/06/22 JPMorgan
JPMorgan 'tentatively bullish' on medtech, sees two best positioned
BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

Earnings
Boston Scientific sees Q2 adjusted EPS 41c-43c consensus 44c » 06:34
04/27/22
04/27
06:34
04/27/22
06:34
BSX

Boston Scientific

$42.63 /

-1.955 (-4.38%)

Sees Q2 revenue up 3%-6%,…

Sees Q2 revenue up 3%-6%, consensus $3.27B. The company said, "The company estimates net sales growth for the second quarter of 2022, versus the prior year period, to be in a range of approximately 3 to 6 percent on a reported basis and organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.19 to $0.23 and adjusted EPS, excluding certain charges (credits), of $0.41 to $0.43."

ShowHide Related Items >><<
BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Boston Scientific assumed with a Buy at Truist
04/06/22 JPMorgan
JPMorgan 'tentatively bullish' on medtech, sees two best positioned
BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

BSX Boston Scientific
$42.63 /

-1.955 (-4.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.